# Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

> **NCT06578949** · PHASE3 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria
- PNH

## Interventions

- **DRUG:** Ravulizumab

## Key facts

- **NCT ID:** NCT06578949
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-10
- **Primary completion:** 2025-05-15
- **Final completion:** 2025-12-22
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06578949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06578949, "Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06578949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*